Drug Trial Radar · NCT05994001
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
78
Actual
Start
Aug 1, 2023
Primary completion
May 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Xuhui Central Hospital, Shanghai; Shanghai Geriatric Medical Center; Affiliated Hospital of Jining Medical University
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this clinical study, we will evaluate the efficacy and safety of cardonilimumab (PD1 monoclonal antibody and CTLA-4 monoclonal antibody bisspecific antibodies) and LM-302 (Claudin18.2-ADC) in Claudin18.2-positive advanced BTC patients who have progressed after SOC and PD1/PD-L1 monoclonal antibody treatment.
Conditions
- Biliary Tract Cancer
- Candonilimab
- Claudin 18.2
Interventions
cardonilizumabDrug
cardonilizumab:PD1 and CTLA-4 bispecific antibody
LM-302Drug
LM-302 :ClAUDIN 18.2-ADC
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR(Phase II)Time frame: 24months
- Incidence of Treatment-Emergent Adverse Events(Phase I)Time frame: 24months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan hospital, Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.